Page 2 - மருத்துவ சோதனைகள் உச்சிமாநாடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மருத்துவ சோதனைகள் உச்சிமாநாடு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மருத்துவ சோதனைகள் உச்சிமாநாடு Today - Breaking & Trending Today

Roche taps into quantum computing software for Alzheimer's disease research


(Getty Images)
Alzheimer’s disease has proven to be stubbornly difficult to unravel, but Roche aims to tap into a new tool that promises to accelerate the process: the quantum computer. 
Through a multi-year partnership with the U.K.’s Cambridge Quantum Computing, the Swiss drugmaker’s task force plans to explore the nascent technology’s potential for designing and delivering new therapeutic compounds. 
The partnership follows a similar endeavor launched earlier this year between Google and Boehringer Ingelheim, which plans to staff its own quantum laboratory as part of the Big Pharma’s digital transformation. Google has also been developing its own quantum hardware, in the Sycamore processor, which it says has outperformed so-called “classical” supercomputers. ....

United Kingdom , Ilyas Khan , Talipot Holdings , Boehringer Ingelheim , Quantum Computing , Big Pharma , Clinical Trials Summit , Premier Educational Event Focused , Decentralized Clinical , Honeywell Ventures , Serendipity Capital , Alvarium Investments , ஒன்றுபட்டது கிஂக்டம் , இழயாச் காந் , போஹெரிங்கர் இஂகல்‌ஹைம் , குவாண்டம் கணினி , பெரியது பார்மா , மருத்துவ சோதனைகள் உச்சிமாநாடு , ப்ரிமியர் கல்வி நிகழ்வு கவனம் , ஹனிவெல் முயற்சிகள் , தற்செயல் மூலதனம் , ஆல்வாரியம் முதலீடுகள் ,

AstraZeneca, BenevolentAI home in on computer-generated target for chronic kidney disease drugs


Jan 27, 2021 11:08am
BenevolentAI’s models work to predict the potential opportunities for drugs that may be overlooked, by identifying the differences in proteins expressed by healthy and diseased cells. (jlcampbell104/CC BY 2.0)
After launching a collaboration nearly two years ago to bring artificial intelligence to kidney drug design, AstraZeneca and BenevolentAI believe they’ve discovered a winner.
Using its biomedical datasets, BenevolentAI’s machine learning platform predicted the existence of a novel target in the underlying cellular mechanisms that cause chronic kidney disease which was later confirmed through experiments by AstraZeneca researchers.
The AI-generated target has been selected by the drugmaker as a new goal for its portfolio, making it the first product to come out of the companies’ partnership, which also focuses on idiopathic pulmonary fibrosis. ....

Eli Lilly , Pernille Laerkegaard Hansen , Clinical Trials Summit , Premier Educational Event Focused , Decentralized Clinical , New England Journal , எலி லில்லி , மருத்துவ சோதனைகள் உச்சிமாநாடு , ப்ரிமியர் கல்வி நிகழ்வு கவனம் , புதியது இங்கிலாந்து இதழ் ,